# Entelexo (YC W21)

Creating a new class of drugs to address incurable autoimmune diseases

## Elevator pitch
We are applying new knowledge of stem cell biology to develop new treatments for autoimmune diseases.

- Canonical URL: https://wefunder.com/entelexo
- Entity ID: wefunder:company:83991
- Last updated: 2026-06-22T05:03:19Z
- Generated at: 2026-06-23T00:52:45Z

## Quick facts
- >$1M raised to date, plus $310k on the same terms
- CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
- Targeting 25M affected by immune-mediated diseases in US, equal to ~$150B in medical costs/year
- Our intellectual property is patent-protected (patent owned by the Company)
- Raising $2M for pre-clinical product development and IND enabling animal studies

## Active fundraises
- wefunder:fundraise:44491: 4(a)(6) successful (USD)
- wefunder:fundraise:44492: 4(a)(6) successful (USD)

## Team
- Milad Riazifar (CEO)
- Todd Schurr (COO)
- Cameron Taylor (CTO)

## Q&A
- Q: Hello, what will happen if you don't raise your full amount? which what BTW?
- Q: I have real interest in this technology. What do you mean by address incurable autoimmune diseases? What does address mean if its incurable?
- Q: Are you responding to questions? I find them pertinent to investment disclosures.
- Q: How is the IP rights around your invention? And how stable are this type of compounds?
- Q: When will you work on ulcerative colitis?